Escitalopram: efficacy and tolerability in the treatment of depression

David S Baldwin

doi:10.12968/hosp.2002.63.11.1912

Escitalopram: efficacy and tolerability in the treatment of depression

Hosp Med. 2002 Nov;63(11):668-71. doi: 10.12968/hosp.2002.63.11.1912.

Author

David S Baldwin¹

Affiliation

¹ Community Clinical Sciences, Research Division, Faculty of Medicine, Health and Biological Sciences, University Department of Mental Health, University of Southampton, Royal South Hants Hospital, Southampton SO14 0YG.

PMID: 12474611
DOI: 10.12968/hosp.2002.63.11.1912

Abstract

Escitalopram is a new antidepressant drug, available for clinical use in many countries. This review describes the properties of escitalopram, summarizes the results of randomized controlled trials, and suggests that escitalopram has advantages over citalopram in the treatment of depression.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antidepressive Agents, Second-Generation / adverse effects
Antidepressive Agents, Second-Generation / therapeutic use*
Anxiety Disorders / drug therapy
Citalopram / adverse effects
Citalopram / therapeutic use*
Depressive Disorder / drug therapy*
Humans
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Antidepressive Agents, Second-Generation
Citalopram